Improvements in symptom severity and daily living with safinamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

被引：1
|
作者：
Szasz, J. [1 ]
Borgohain, R. [2 ]
Bhatt, M. [3 ]
Rossetti, S. [4 ]
Lucini, V. [4 ]
Anand, R. [5 ]
机构：
[1] Emergency Cty Hosp Targu Mures, Targu Mures, Romania
[2] Nizams Inst Med Sci, Hyderabad, India
[3] Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Mumbai, Maharashtra, India
[4] Newron Pharmaceut SpA, Bresso, Italy
[5] APC AG, St Moritz, Switzerland
来源：
PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷
关键词：
D O I：
10.1016/S1353-8020(09)70459-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.108
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [41] Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial
    Gu, Si-chun
    Zhou, Jie
    Ye, Qing
    Yuan, Can-xing
    JOURNAL OF INTEGRATIVE MEDICINE-JIM, 2021, 19 (02): : 120 - 128
  • [42] The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study
    Ferreira, Joaquim
    Poewe, Werner
    Rascol, Olivier
    Stocchi, Fabrizio
    Antonini, Angelo
    Moreira, Joana
    Rocha, Jose
    Soares-Da-Silva, Patricio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 265 - 266
  • [43] Pingchan granule for depressive symptoms in parkinson's disease:A randomized, double-blind, placebo-controlled trial
    Si-chun Gu
    Jie Zhou
    Qing Ye
    Can-xing Yuan
    Journal of Integrative Medicine, 2021, 19 (02) : 120 - 128
  • [44] Transdermal Rotigotine in Early Stage Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Trial
    Mizuno, Yoshikuni
    Nomoto, Masahiro
    Kondo, Tomoyoshi
    Hasegawa, Kazuko
    Murata, Miho
    Takeuchi, Masahiro
    Ikeda, Junji
    Tomida, Takayuki
    Hattori, Nobutaka
    MOVEMENT DISORDERS, 2013, 28 (10) : 1447 - 1450
  • [45] The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson's disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Stocchi, F.
    Antonini, A.
    Moreira, J.
    Rocha, J.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2021, 36 : S172 - S173
  • [46] Clozapine improves dyskinesias in Parkinson disease - A double-blind, placebo-controlled study
    Durif, F
    Debilly, B
    Galitzky, M
    Morand, D
    Viallet, F
    Borg, M
    Thobois, S
    Broussolle, E
    Rascol, O
    NEUROLOGY, 2004, 62 (03) : 381 - 388
  • [47] Donepezil treatment in Parkinson's disease with dementia: A double-blind, placebo-controlled crossover study
    Aarsland, D
    Larsen, JP
    Janvin, C
    Laake, K
    NEUROLOGY, 2001, 56 (08) : A128 - A128
  • [48] Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Multicenter Study
    Goetz, Christopher G.
    Stebbins, Glenn T.
    Chung, Kathryn A.
    Nicholas, Anthony P.
    Hauser, Robert A.
    Merkitch, Douglas
    Stacy, Mark A.
    MOVEMENT DISORDERS, 2017, 32 (09) : 1335 - 1336
  • [49] Pilot study of H2 therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial
    Yoritaka, Asako
    Takanashi, Masashi
    Hirayama, Masaaki
    Nakahara, Toshiki
    Ohta, Shigeo
    Hattori, Nobutaka
    MOVEMENT DISORDERS, 2013, 28 (06) : 836 - 839
  • [50] Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study
    Pierantozzi, Mariangela
    Placidi, Fabio
    Liguori, Claudio
    Albanese, Maria
    Imbriani, Paola
    Marciani, Maria Grazia
    Mercuri, Nicola Biagio
    Stanzione, Paolo
    Stefani, Alessandro
    SLEEP MEDICINE, 2016, 21 : 140 - 144
12345